{"id":"NCT00456508","sponsor":"Shire","briefTitle":"Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)","officialTitle":"Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04-01","primaryCompletion":"2010-06-01","completion":"2010-09-01","firstPosted":"2007-04-05","resultsPosted":"2012-12-28","lastUpdate":"2021-06-08"},"enrollment":147,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"ecallantide","otherNames":["DX-88"]}],"arms":[{"label":"DX-88 (ecallantide)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.","primaryOutcome":{"measure":"Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing","timeFrame":"4 hrs post dose after every episode","effectByArm":[{"arm":"DX-88 (Ecallantide)","deltaMin":-1.04,"sd":0.773}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":41,"countries":["United States","Canada","Jordan"]},"refs":{"pmids":["24712435","23878046","23548529","23548526"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":147},"commonTop":["hereditary angioedema","nausea","headache","abdominal pain","upper respiratory tract infection"]}}